Selected article for: "adverse effect and study aim"

Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018
  • Document date: 2018_10_25
  • ID: 60ceejq1_241
    Snippet: Fenbendazole administered to two dogs at 50 mg/kg was not detectable. Dogs were subsequently treated with 100 mg/kg (n = 4) and then 200 mg/kg (n = 2 due to adverse effect), resulting in an average peak plasma concentration (ng/ml) of 131. 5 The aim of the study was to determine the precision of the novel MRI-based patient-individual stereotactic brain biopsy device in dogs......
    Document: Fenbendazole administered to two dogs at 50 mg/kg was not detectable. Dogs were subsequently treated with 100 mg/kg (n = 4) and then 200 mg/kg (n = 2 due to adverse effect), resulting in an average peak plasma concentration (ng/ml) of 131. 5 The aim of the study was to determine the precision of the novel MRI-based patient-individual stereotactic brain biopsy device in dogs.

    Search related documents:
    Co phrase search for related documents
    • adverse effect and plasma concentration: 1, 2, 3, 4
    • adverse effect and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • biopsy device and patient individual stereotactic brain biopsy device: 1
    • biopsy device and stereotactic brain: 1
    • biopsy device and stereotactic brain biopsy device: 1
    • biopsy device and study aim: 1
    • ng ml plasma concentration and peak ng ml plasma concentration: 1, 2
    • ng ml plasma concentration and plasma concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • ng ml plasma concentration and study aim: 1
    • patient individual stereotactic brain biopsy device and stereotactic brain: 1
    • patient individual stereotactic brain biopsy device and stereotactic brain biopsy device: 1
    • peak ng ml plasma concentration and plasma concentration: 1, 2
    • plasma concentration and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30